Dietary supplementation with highly purified eicosapentaenoic acid and docosahexaenoic acid does not influence PAI-1 activity

Thrombosis Research

Volumn 98, Issue 2, 2000, Pages 123-132

  Hansen, John Bjarne ^a   Grimsgaard, Sameline ^a   Nordøy, Arne ^a   Bønaa, Kaare H ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Fibrinolysis; n 3 fatty acids; PAI 1 activity; Serum lipids

Indexed keywords

CORN OIL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FAT INTAKE; FATTY ACID BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARTERIOSCLEROSIS; DIETARY FATS, UNSATURATED; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS; TRIGLYCERIDES;

EID: 0034655115     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00223-6     Document Type: Article

References (52)

1. Davies M.J., Thomas A.C. Plaque fissuring. The cause of acute myocardial infarction, sudden death, and crescendo angina Br Heart J. 53:1985;363-373.
2. De Wood M.A., Spores J., Notske R., Mouser L.T., Burroughs R., Golden M.S., Lang H.T. Prevalence of total coronary occlusion during the early hours of transmural infarction. N Engl J Med. 303:1980;897-902.
3. Stokes J. Dyslipidemia as a risk factor for cardiovascular disease and untimely death: The Framingham study. In: Stokes J III, Mancini M., editors. New York, Raven Press, Ltd. Atherosclerosis Reviews 1988;18:49-57.
4. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:3015-23.
5. Kruithof E.K.O., Tran-Thang C., Ransijn A., Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood. 64:1984;907-913.
6. Dawson S., Henney A. The status of PAI-1 as a risk for arterial and thrombotic disease. A review Atherosclerosis. 95:1992;105-117.
7. Hamsten A., Wiman B., deFaire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
8. Paramo J.A., Colucci M., Collen D., Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J. 291:1985;573-574.
9. Jansson J.H., Nilsson T.K., Olofsson B.O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 12:1991;157-161.
10. Hellsten G., Boman K., Bjerke P., Blom P., Nilsson T.K. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease. A cross-sectional study in Norsjø, Sweden Eur Heart J. 13:1992;57-60.
11. Elkeles R.S., Chakrabarti R., Vickers M., Stirling Y., Meade T.W. Effect of treatment of hyperlipidemia on haemostatic variables. Br Med J. 281:1980;973-974.
12. Andersen P., Smith P., Seljeflot I., Brataker S., Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemostas. 63:1990;174-177.
13. Dyerberg J., Bang H.O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 2:1979;433-435.
14. Hirai A., Hamazaki T., Terano T., Nishikawa T., Tamura Y., Kumagi A. Eicosapentaenoic acid and platelet function in Japanese. Lancet. 2:1980;1132-1133.
15. Grimsgaard S., Bønaa K.H., Hansen J.B., Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol lowering effects, but divergent effects on plasma fatty acids. Am J Clin Nutr. 66:1997;649-659.
16. Hansen J.B., Olsen J.O., Wilsgaard L., Lyngmo V., Svensson B. Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men. Eur J Clin Nutr. 47:1993;497-507.
17. Hansen J.B., Lyngmo V., Svensson B., Nordøy A. Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). Arterioscler Thromb. 13:1993;98-104.
18. Barcelli U., Glas-Greenwalt P., Pollak V.E. Enhancing effect of dietary supplementation with w-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res. 39:1985;307-312.
19. Eritsland J., Arnesen H., Seljeflot I., Kierulf P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis. 6:1995;17-22.
20. Emeis J.J., van Houwelingen A.C., van den Hoogen H., Hornstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. Blood. 74:1989;233-237.
21. Folch J., Lees M., Stanley S. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 226:1957;497-509.
22. Kaluzny M.A., Duncan L.A., Merritt M.V., Epps D.E. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res. 26:1985;135-140.
23. Eriksson E., Rȧnby M., Gyzander E., Risberg B. Determination of plasminogen activator inhibitor in plasma using tPA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res. 50:1988;91-101.
24. Kruithof E.K.O. Plasminogen activator inhibitor type 1. Biochemical, biological and clinical aspects Fibrinolysis. 2(Suppl 2):1988;59-70.
25. SAS Institute, Inc. SAS/STAT guide for personal computers, version 6. Edition. Cary, NC: SAS Institute; 1987/1990.
26. Oosthuizen W., Vorster H.H., Jerling J.C., Barward H.C., Smuls C.M., Silvis N., Kruger A., Venter H.C. Both fish oil and olive lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb Haemostas. 72:1994;557-562.
27. Hellsten G., Boman K., Saarem K., Hallmans G., Nilsson T.K. Effect on fibrinolytic activity of corn oil and fish oil preparation enriched with omega-3 polyunsaturated fatty acids in a long-term study. Curr Med Res Opin. 13:1993;133-139.
28. Berg Schmidt E., Varming K., Ernst E., Madsen P., Dyerberg J. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb Haemostas. 63:1990;1-5.
29. Berg Schmidt E., Lervang H.H., Varning K., Madsen P., Dyerberg J. Long-term supplementation with n-3 fatty acids, I. Effect on blood lipids, haemostasis and blood pressure Scand J Clin Lab Invest. 52:1992;221-228.
30. Iacoviello L., Amore C., De Curtis A., Tacconi M.T., de Gaetano G., Cerletti C., Donati M.B. Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids. Arterioscler Thromb. 12:1992;1191-1197.
31. Takimoto G., Galang J., Lee G.K., Bradlow B.A. Plasma fibrinolytic activity after ingestion of omega-3 fatty acids in human subjects. Thromb Res. 54:1989;573-582.
32. Marckmann P., Jespersen J., Leth T., Sandström B. Effect of fish diet versus meat diet on blood lipids, coagulation and fibrinolysis in healthy young men. J Int Med. 229:1991;317-323.
33. Prisco D., Paniccia R., Filippini M., Francalanci I., Bandinelli B., Comeglio P., Rostagno C., Abbate R., Neri Serneri G.G. No changes in PAI-1 levels after four-month n-3 PUFA ethyl ester supplementation in healthy subjects. Thromb Res. 76:1994;237-244.
34. Haglund O., Mehta J.L., Saldeen T. Effects of fish oil on some parameters of fibrinolysis and lipoprotein (a) in healthy subjects. Am J Cardiol. 74:1994;189-192.
35. Nilsen D.W.T., Almdahl S.M., Svensson B., Vaage J., Rasmussen K., Østerud B. Lipopolysaccharide induced monocyte thromboplastin synthesis and coagulation responses in patients undergoing coronary bypass surgery after preoperative supplementation with n-3 fatty acids. Thromb Haemostas. 70:1993;900-902.
36. Berg Schmidt E., Dalby Kristensen S., Dyerberg J. The effect of fish oil on lipids, coagulation and fibrinolysis in patients with angina pectoris. Artery. 15:1988;316-329.
37. Berg Schmidt E., Ernst E., Varning K., Pedersen J.O., Dyerberg J. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidemia. Thromb Haemostas. 62:1989;797-801.
38. Boberg M., Pollare T., Siegbahn A., Vessby B. Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 22:1992;645-650.
39. Spannagl M., Drummer C., Fröschl H., von Schacky C., Landgraf-Leurs M.M.C., Landgraf R., Schramm W. Plasmatic factors of haemostasis remain essentially unchanged except for PAI activity during n-3 fatty acid intake in type 1 diabetes mellitus. Blood Coagul Fibrinolysis. 2:1991;259-265.
40. Toft I., Bønaa K.H., Ingebretsen O.C., Nordøy A., Jensen T. Fibrinolytic function after dietary supplementation with omega-3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol. 17:1997;814-819.
41. Juhan-Vague I., Vague P., Alessi M.C., Ardissone J.P., Heim M., Vague P. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor1. Diabetes Metabolism. 2:1986;250-253.
42. Hamsten A., Walldius G., Szaposi A., Blomback M., De Faire U., Dahlen G., Landou C., Wiman B. Plasmiongen activator inhibitor in plasma. Risk factor for recurrent myocardial infarction Lancet. 2:1987;3-9.
43. Mehta J., Mehta P., Lawson D., Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease. Correlation with age and serum triglyceride concentrations J Am Coll Cardiol. 9:1987;263-268.
44. Berg Schmidt E., Dyerberg J. Omega-3 fatty acids. Current status in cardiovascular medicine Drugs. 47:1994;405-424.
45. Nordøy A. Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine? Drugs. 42:1991;331-342.
46. Toft I., Bønaa K.H., Ingebretsen O.C., Nordøy A., Birkeland K.I., Jensen T. Gender differences in the relationship between plasma plasminogen activator inhibitor-activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol. 17:1997;553-559.
47. Stiko-Rahm A., Wiman B., Hamsten A., Nilsson J. Secretion of plasminogen activator inhibitor-from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10:1990;1067-1073.
48. Kaneko T., Wada H., Wakita Y., Minamikawa K., Nakase T., Mori Y., Deguchi K., Shirakawa S. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis. 5:1994;385-392.
49. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., Sironi L., Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 12:1992;19-27.
50. Haire W.D. Gemfibrozil predictably lower triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis. Thromb Res. 64:1991;493-501.
51. Keber D., Cevc M., Keber I. Increased PAI-1 antigen after short-term treatment with gemfibrozil as opposed to unchanged levels after bezafibrate and lovastatin. Thromb Haemostas. 65:1991;1276. 2104).(abstract no.
52. Broijersen A., Eriksson M., Wiman B., Angelin B., Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol. 16:1996;511-516.